Retinoblastoma seeds: impact on American Joint Committee on Cancer clinical staging.
Por:
Tomar AS, Finger PT, Gallie B, Kivelä T, Mallipatna A, Zhang C, Zhao J, Wilson M, Brennan R, Burges M, Kim J, Berry JL, Jubran R, Khetan V, Ganeshan S, Yarovoy A, Yarovaya V, Kotova E, Volodin D, Yousef Y, Nummi K, Ushakova TL, Yugay OV, Polyakov VG, Ramirez-Ortiz MA, Esparza-Aguiar E, Chantada GL, Schaiquevich P, Fandiño AC, Yam JC, Lau WW, Lam CP, Sharwood P, Moorthy S, Long QB, Essuman VA, Renner LA, Semenova E, Català-Mora J, Correa Llano M, Carreras-Bertran E, American Joint Committee on Cancer Ophthalmic Oncology Task Force and American Joint Committee on Cancer Ophthalmic Oncology Task
Publicada:
1 ene 2023
Ahead of Print:
2 ago 2021
Resumen:
AIM: To investigate whether the American Joint Committee on Cancer (AJCC) clinical category cT2b needs to be subclassified by the type and distribution of retinoblastoma (RB) seeding. METHODS: Multicentre, international registry-based data were collected from RB centres enrolled between January 2001 and December 2013. 1054 RB eyes with vitreous or subretinal seeds from 18 ophthalmic oncology centres, in 13 countries within six continents were analysed. Local treatment failure was defined as the use of secondary enucleation or external beam radiation therapy (EBRT) and was estimated with the Kaplan-Meier method. RESULTS: Clinical category cT2b included 1054 eyes. Median age at presentation was 16.0 months. Of these, 428 (40.6%) eyes were salvaged, and 430 (40.8%) were treated with primary and 196 (18.6%) with secondary enucleation. Of the 592 eyes that had complete data for globe salvage analysis, the distribution of seeds was focal in 143 (24.2%) and diffuse in 449 (75.8%). The 5-year Kaplan-Meier cumulative globe-salvage (without EBRT) was 78% and 49% for eyes with focal and diffuse RB seeding, respectively. Cox proportional hazards regression analysis confirmed a higher local treatment failure risk with diffuse seeds as compared with focal seeds (hazard rate: 2.8; p<0.001). There was insufficient evidence to prove or disprove an association between vitreous seed type and local treatment failure risk(p=0.06). CONCLUSION: This international, multicentre, registry-based analysis of RB eyes affirmed that eyes with diffuse intraocular distribution of RB seeds at diagnosis had a higher risk of local treatment failure when compared with focal seeds. Subclassification of AJCC RB category cT2b into focal vs diffuse seeds will improve prognostication for eye salvage.
Filiaciones:
Tomar AS:
Department of Ocular Tumor and Orbital Disease, New York Eye Cancer Center, New York, New York, USA
Gallie B:
The Eye Cancer Clinic, Princess Margaret Cancer Centre, and Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, Toronto, Ontario, Canada
Kivelä T:
Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Mallipatna A:
Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, Toronto, Ontario, Canada
Department of Ophthalmology and Vision Sciences, Narayana Nethralaya, Bangalore, Karnataka, India
Zhang C:
Pediatric Oncology Center, Beijing Children's Hospital, Beijing, China
Zhao J:
Pediatric Oncology Center, Beijing Children's Hospital, Beijing, China
Wilson M:
Ophthalmic Oncology, Department of Ophthalmology Hamilton Eye Institute, The University of Tennessee Health Science Center, Memphis, Tennessee, USA
Brennan R:
Department of Ophthalmology, St Jude Children's Research Hospital, Memphis, Tennessee, USA
Burges M:
Ophthalmic Oncology, Department of Ophthalmology Hamilton Eye Institute, The University of Tennessee Health Science Center, Memphis, Tennessee, USA
Kim J:
USC Roski Eye Institute, Keck Medical School of the University of Southern California, and The Vision Center at Children's Hospital Los Angeles, Los Angeles, California, USA
Berry JL:
Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, California, USA
Jubran R:
Cancer and Blood Diseases, Childrens Hospital Society of Los Angeles, Los Angeles, California, USA
Khetan V:
Vitreo Retinal Services, Sankara Nethralaya, Chennai, Tamil Nadu, India
Ganeshan S:
Vitreo Retinal Services, Sankara Nethralaya, Chennai, Tamil Nadu, India
Yarovoy A:
Ocular Oncology Department, S Fyodorov Eye Microsurgery Federal State Institution, Moskva, Moskva, Russian Federation
Yarovaya V:
Ocular Oncology Department, S Fyodorov Eye Microsurgery Federal State Institution, Moskva, Moskva, Russian Federation
Kotova E:
Ocular Oncology Department, S Fyodorov Eye Microsurgery Federal State Institution, Moskva, Moskva, Russian Federation
Volodin D:
Ocular Oncology Department, S Fyodorov Eye Microsurgery Federal State Institution, Moskva, Moskva, Russian Federation
Yousef Y:
Department of Surgery (Ophthalmology), King Hussein Cancer Center, Amman, Jordan
Nummi K:
Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Ushakova TL:
Pediatric Oncology and Hematology, N N Blokhin NMRCO, Moskva, Russian Federation
Russian Academy of Postgraduate Medical Education, Moskva, Russian Federation
Yugay OV:
Pediatric Oncology and Hematology, N N Blokhin NMRCO, Moskva, Russian Federation
Polyakov VG:
Pediatric Oncology and Hematology, N N Blokhin NMRCO, Moskva, Russian Federation
Russian Academy of Sciences, Moskva, Russian Federation
Ramirez-Ortiz MA:
Department of Ophthalmology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico
Esparza-Aguiar E:
Department of Ophthalmology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico
Chantada GL:
Ophthalmology, Paediatric Hospital Dr Juan Garrahan Library, Buenos Aires, Argentina
Schaiquevich P:
Precision Medicine Coordination Hospital J. P. Garrahan, and CONICET (National Scientific and Technical Research Council), Buenos Aires, Argentina
Fandiño AC:
Ophthalmology, Paediatric Hospital Dr Juan Garrahan Library, Buenos Aires, Argentina
Yam JC:
Opthamology and Visual Sciences, The Chinese University of Hong Kong Faculty of Medicine, Hong Kong, Hong Kong
Lau WW:
Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, Hong Kong, Hong Kong
Lam CP:
Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, Hong Kong, Hong Kong
Sharwood P:
Save Sight Institute, Discipline of Ophthalmology, The University of Sydney Sydney Medical School, Sydney, New South Wales, Australia
Moorthy S:
Retinoblastoma Unit, Department of Oncology, Hospital Sant Joan de Déu. Esplugues de Llobregat, Barcelona, Spain
Long QB:
KK Women's and Children's Hospital, Singapore
Essuman VA:
Department of Child Heath, University of Ghana Medical School, Accra, Ghana
Renner LA:
Department of Child Health, University of Ghana Medical School, Accra, Greater Accra, Ghana
Semenova E:
Department of Ocular Tumor and Orbital Disease, New York Eye Cancer Center, New York, New York, USA
Català-Mora J:
Ophthalmology, Hospital Sant Joan de Deu, Barcelona, Catalunya, Spain
:
Ophthalmology, Hospital Sant Joan de Deu, Barcelona, Catalunya, Spain
Carreras-Bertran E:
Ophthalmology, Hospital Sant Joan de Deu, Barcelona, Catalunya, Spain
hybrid, Green Published
|